This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

This study has been completed.
Sponsor:
Collaborator:
Duke Clinical Research Institute
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00089895
First received: August 17, 2004
Last updated: April 3, 2017
Last verified: April 2017
Results First Received: November 13, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Myocardial Ischemia
Acute Coronary Syndrome
Interventions: Drug: Eptifibatide (Integrilin)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients in both treatment groups who were undergoing PCI could receive unblinded eptifibatide provisionally immediately before or during percutaneous coronary intervention (PCI) at the discretion of the investigator.

Reporting Groups
  Description
Eptifibatide Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.
Placebo Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.

Participant Flow:   Overall Study
    Eptifibatide   Placebo
STARTED   4722 [1]   4684 [1] 
COMPLETED   4687 [2]   4642 [2] 
NOT COMPLETED   35   42 
Consent Withdrawn                11                14 
Technical reason                7                2 
Surgery                0                1 
Bleeding                0                2 
Physician Decision                3                7 
Exclusion criteria met                6                6 
Not otherwise specified                4                8 
Missing                4                2 
[1] Number of Subjects Randomized with Intent to Treat
[2] Number of Subjects treated



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Eptifibatide Eptifibatide in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.
Placebo Placebo in addition to standard of care which includes usage of aspirin, unfractionated heparin or low-molecular weight heparin.
Total Total of all reporting groups

Baseline Measures
   Eptifibatide   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 4722   4684   9406 
Age 
[Units: Years]
Mean (Standard Deviation)
 66.4  (10.6)   66.7  (10.7)   66.6  (10.7) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      1513  32.0%      1462  31.2%      2975  31.6% 
Male      3209  68.0%      3222  68.8%      6431  68.4% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out.   [ Time Frame: 96 hours after randomization ]

2.  Secondary:   Incidence of the Composite of Death/MI.   [ Time Frame: 30 days after randomization ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
e-mail: ClinicalTrialsDisclosure@merck.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00089895     History of Changes
Other Study ID Numbers: P03684
Study First Received: August 17, 2004
Results First Received: November 13, 2009
Last Updated: April 3, 2017